Mirati Therapeutics, Inc. (MRTX): Price and Financial Metrics


Mirati Therapeutics, Inc. (MRTX): $186.39

-3.90 (-2.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 508

in industry

MRTX POWR Grades


  • Value is the dimension where MRTX ranks best; there it ranks ahead of 42.23% of US stocks.
  • MRTX's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • MRTX ranks lowest in Momentum; there it ranks in the 4th percentile.

MRTX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for MRTX is 0.01 -- better than just 7.59% of US stocks.
  • With a price/sales ratio of 732.72, Mirati Therapeutics Inc has a higher such ratio than 99.17% of stocks in our set.
  • As for revenue growth, note that MRTX's revenue has grown 637.34% over the past 12 months; that beats the revenue growth of 98.68% of US companies in our set.
  • Stocks that are quantitatively similar to MRTX, based on their financial statements, market capitalization, and price volatility, are RCUS, FATE, KLDO, CNCE, and CARA.
  • MRTX's SEC filings can be seen here. And to visit Mirati Therapeutics Inc's official web site, go to www.mirati.com.

MRTX Valuation Summary

  • MRTX's price/sales ratio is 667.2; this is 17457.89% higher than that of the median Healthcare stock.
  • Over the past 99 months, MRTX's price/sales ratio has gone NA NA.
  • Over the past 99 months, MRTX's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for MRTX.

Stock Date P/S P/B P/E EV/EBIT
MRTX 2021-08-31 667.2 7.8 -17.9 -17.4
MRTX 2021-08-30 664.0 7.7 -17.8 -17.3
MRTX 2021-08-27 641.6 7.5 -17.2 -16.7
MRTX 2021-08-26 640.0 7.4 -17.1 -16.7
MRTX 2021-08-25 612.8 7.1 -16.4 -15.9
MRTX 2021-08-24 581.4 6.8 -15.6 -15.1

MRTX Growth Metrics

  • Its 5 year price growth rate is now at 339.94%.
  • Its 3 year net cashflow from operations growth rate is now at -66.92%.
  • The 2 year net cashflow from operations growth rate now stands at -216.5%.
Over the past 33 months, MRTX's revenue has gone up $3,665,000.

The table below shows MRTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 13.132 -356.967 -490.533
2021-03-31 13.132 -322.943 -406.962
2020-12-31 13.398 -271.531 -357.937
2020-09-30 12.217 -237.012 -329.226
2020-06-30 1.781 -193.123 -296.163
2020-03-31 2.358 -172.248 -258.999

MRTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRTX has a Quality Grade of D, ranking ahead of 13.87% of graded US stocks.
  • MRTX's asset turnover comes in at 0.011 -- ranking 388th of 681 Pharmaceutical Products stocks.
  • LUMO, SUPN, and RETA are the stocks whose asset turnover ratios are most correlated with MRTX.

The table below shows MRTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.011 1 -0.668
2021-03-31 0.013 1 -0.658
2020-12-31 0.015 1 -0.750
2020-09-30 0.020 1 -0.781
2020-06-30 0.003 1 -0.737
2020-03-31 0.004 1 -0.765

MRTX Price Target

For more insight on analysts targets of MRTX, see our MRTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $216.18 Average Broker Recommendation 1.56 (Moderate Buy)

MRTX Stock Price Chart Interactive Chart >

Price chart for MRTX

MRTX Price/Volume Stats

Current price $186.39 52-week high $249.42
Prev. close $190.29 52-week low $131.46
Day low $185.58 Volume 393,500
Day high $195.99 Avg. volume 481,630
50-day MA $166.66 Dividend yield N/A
200-day MA $171.74 Market Cap 9.62B

Mirati Therapeutics, Inc. (MRTX) Company Bio


Mirati Therapeutics develops molecularly targeted cancer treatments that are intended to inhibit tumor growth. The company was founded in 1995 and is based in San Diego, California.


MRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

MRTX Latest Social Stream


Loading social stream, please wait...

View Full MRTX Social Stream

Latest MRTX News From Around the Web

Below are the latest news stories about Mirati Therapeutics Inc that investors may wish to consider to help them evaluate MRTX as an investment opportunity.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares Acquired by Neuberger Berman Group LLC

Neuberger Berman Group LLC increased its holdings in Mirati Therapeutics, Inc. (NASDAQ:MRTX) by 14.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 20,257 shares of the biotechnology companys stock after purchasing an additional 2,584 shares during the quarter. Neuberger Berman Group LLCs holdings in []

Transcript Daily | October 24, 2021

Analysts Expect Mirati Therapeutics, Inc. (NASDAQ:MRTX) Will Post Earnings of -$2.86 Per Share

Wall Street analysts expect that Mirati Therapeutics, Inc. (NASDAQ:MRTX) will post ($2.86) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Mirati Therapeutics earnings, with the highest EPS estimate coming in at ($2.22) and the lowest estimate coming in at ($3.41). Mirati Therapeutics reported earnings of []

Transcript Daily | October 23, 2021

California Public Employees Retirement System Cuts Holdings in Mirati Therapeutics, Inc. (NASDAQ:MRTX)

California Public Employees Retirement System cut its position in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) by 10.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 81,742 shares of the biotechnology companys stock after selling 9,877 shares during the quarter. California Public Employees []

Transcript Daily | October 22, 2021

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares Purchased by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC boosted its holdings in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) by 7.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,000,000 shares of the biotechnology companys stock after purchasing an additional 325,000 shares during the period. Mirati Therapeutics []

Dakota Financial News | October 20, 2021

MRTX Crosses Above Key Moving Average Level

In trading on Tuesday, shares of Mirati Therapeutics Inc (Symbol: MRTX) crossed above their 200 day moving average of $173.90, changing hands as high as $177.71 per share. Mirati Therapeutics Inc shares are currently trading up about 2.5% on the day. The chart below shows the

iShook Finance | October 12, 2021

Read More 'MRTX' Stories Here

MRTX Price Returns

1-mo 12.04%
3-mo 17.82%
6-mo 13.30%
1-year -5.23%
3-year 437.61%
5-year 3,288.91%
YTD -15.14%
2020 70.45%
2019 203.77%
2018 132.44%
2017 284.21%
2016 -84.97%

Continue Researching MRTX

Want to see what other sources are saying about Mirati Therapeutics Inc's financials and stock price? Try the links below:

Mirati Therapeutics Inc (MRTX) Stock Price | Nasdaq
Mirati Therapeutics Inc (MRTX) Stock Quote, History and News - Yahoo Finance
Mirati Therapeutics Inc (MRTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8361 seconds.